A Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of Baxdrostat in Participants with Uncontrolled Hypertension on Two or More Medications including Participants with Resistant Hypertension

Uncontrolled hypertension (uTHN) defined as blood pressure that remains higher than goal levels despite patients being treated with 2 anti-hypertensive agents, including a diuretic. Resistant hypertension (rHTN) defined as blood pressure that remains higher than goal levels despite the use of at least 3 anti hypertensive drugs of different classes at maximum tolerated dose, including a diuretic.

Change from baseline in seated systolic blood pressure for 2 mg baxdrostat., Change from baseline in seated systolic blood pressure for 1 mg baxdrostat., Safety and tolerability will be evaluated in terms of AEs, vital signs, clinical and laboratory assessments.

Change from randomised withdrawal baseline (Week 24) in seated systolic blood pressure (SBP) for 2 mg baxdrostat., Change from baseline in seated SBP for 2 mg baxdrostat., Change from baseline in seated diastolic blood pressure (DBP) for 2 mg baxdrostat., Achieving seated SBP < 130 mmHg for 2 mg baxdrostat., Change from baseline in seated SBP for 1 mg baxdrostat., Change from baseline in seated DBP for 1 mg baxdrostat., Achieving seated SBP < 130 mmHg for 1 mg baxdrostat.

No related papers found yet.

Papers published before 2007-09-01 may not appear yet. Historical indexing is in progress.

Austria, Belgium, Bulgaria, Czechia, Denmark, France, Germany, Hungary, Italy, Netherlands, Poland, Slovakia, Spain, Sweden